U.S. Physical Therapy vs Tenet Healthcare: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

U.S. Physical Therapy, Inc. (USPH)

Q3 20261 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.

August 20261 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.

Latest1 Aug – 14 Sep 2026

▲2

USPH grows visits and buys clinics, but costs squeeze profit

Record visits and rates, but profit squeezed by costs USPH's Q2 revenue rose 8.5% to $214.1 million, with record per-visit rates and all-time-high visits per clinic. But net income fell to $9.9 million from $12.4 million as employee health costs and new hiring ate into margins. Growth is real, yet profit is shrinking — that tug-of-war is what moves the stock.
It is the core new earnings result and explains the mixed pressure on USPH's price.
Hospital alliances open a new growth path Management is pushing partnerships with hospital systems like NYU Langone, now 60 New York locations, which bring steadier patient volumes and flat, predictable per-visit payments. The injury-prevention unit has grown to about $120 million in revenue with roughly double the margins of the core therapy business.
It is the newest strategic driver management is betting on for future growth.
New permanent CFO ends leadership uncertainty USPH named Nchacha Etta, a former Omnicell and Johnson & Johnson Vision finance chief, as CFO effective September 1, ending the interim period that began in April. A settled finance leadership is a modest positive, though it does not change the underlying business.
It is a genuinely new company event that removes an overhang on the stock.
Acquisitions keep growing, but debt and cash tighten USPH closed three deals this year for $37.6 million, adding about $27 million of annual revenue, and reaffirmed full-year EBITDA guidance of $102–106 million. But cash fell to $24.9 million while credit borrowings rose to $221 million, so the buying spree is being funded with debt.
It shows the growth engine and its financing cost, a real counterweight for investors.

Tenet Healthcare Corporation (THC)

Q3 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

August 202621 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.

Latest21 Jun – 14 Sep 2026

▲4

Tenet's outpatient engine and AI edge drive raised outlook and buybacks

USPI outpatient growth powers results Tenet's USPI surgery-center business is growing fast, with Q2 revenues up 9.3% and strong demand for outpatient joint replacements. This shift to lower-cost care lifts profit and supports a higher full-year outlook, pushing THC shares up.
USPI is the main growth engine and directly explains the raised guidance and positive price impact.
Strong Q2 earnings and raised 2026 outlook Tenet reported Q2 net income of $826 million and raised full-year EBITDA guidance by $295 million at the midpoint. The stock jumped over 16% on the beat, as investors saw stronger profits ahead.
This is the core new financial event that directly moved the stock and improved future expectations.
Bigger buyback returns cash to shareholders Tenet added $2 billion to its share repurchase program, leaving about $2.1 billion available. Buying back stock reduces shares outstanding, which can lift earnings per share and support the stock price.
The expanded buyback is a new capital return action that boosts per-share value and investor confidence.
AI could give hospitals a lasting profit edge UBS says hospitals like Tenet may keep AI gains longer than insurers, using it for billing, denial appeals, and staffing. If Tenet holds that lead, margins could improve over years, making the stock more attractive.
This is a new analyst view on a long-term profit driver that supports the bullish case for THC.